Skip to main content
. 2020 Aug 20;5(16):e133868. doi: 10.1172/jci.insight.133868

Figure 4. T2DM subjects treated with metformin show a region-specific decrease in the number of iba1-ir microglial soma and ramifications in the IFN.

Figure 4

(A–H) iba1-ir microglia in the IFN of a CTRL subject (A), T2DM subject with no insulin no metformin (B), with metformin and insulin (C), or with insulin (D) (higher magnification of the areas framed in A–D are shown in E–H, respectively). (I–K) Comparison in the neuropeptide Y (NPY) and POMC region of: iba1-ir soma number (I), iba1-ir soma size (J), and number of iba1-ir ramifications (K). (L–N) Antidiabetic treatment-associated effects in the NPY and POMC region on iba1-ir soma number (L), iba1-ir soma size (M), and number of iba1-ir ramifications (N). 3V, third ventricle. Scale bars: 500 μm (D), 50 μm (H). Data are represented as mean ± SEM. Significance is calculated using 2-way ANOVA in L and N. All P values were corrected for multiple testing using the Benjamini-Hochberg criterion. *P < 0.05.